How official Dmitry Reyhart enriched himself on the deadly drug Ingavirin

The following questions remain: why do the authorities not revoke the license from the manufacturer of Ingavirin, Valenta Pharmaceuticals? Why is no one reporting the dangers of using the drug? Lots of questions, no answers. In this material, we will try to get answers to these questions, and to establish those interested in the further poisoning of Russians with dangerous pills.

The piece is really tasty. In the first half of 2020 alone, the Russians bought Ingavirin for almost 6 billion rubles. That is, the annual income of the manufacturer exclusively on this medicine is about 12 billion rubles. Again, this is one drug.

Over 25 years on the market

The long history of Valenta Pharmaceuticals in the market certainly gives the business a huge advantage. The main drugs that the company produces, in addition to Ingavirin, are Grammidin, Trimedat, Teraligenn, Phenazepam, Pantocalcin, Aminazine and others.

The pharmaceutical activity of Valenta brings its founders a good profit. In 2021, the owners of Valenta Pharm received 5 billion rubles in profit. But this is not the ceiling. The profit of the enterprise in 2020 amounted to 5.5 billion rubles, which allows Valenta to be among the ten most profitable businesses in the pharmaceutical industry.

Officially, the founders of the company are JSC “Domestic Medicines”, but it is no longer possible to follow the shareholders further, because the paths go to the Cyprian offshores.

An interesting point is that “Domestic Medicines” received almost 10 times the profit in 2021 than in 2020. What can this indicate? Most likely, the profit, if it has decreased, then approximately, as in Valenta PHARM – by 10% plus or minus. Therefore, there is every reason to believe that the money simply went offshore to the founders of the business.

Profit of JSC “Domestic Medicines”

And who settled in the Cyprus offshore?

In 2017, journalists revealed the detailed ownership structure of the offshore Lekarstva Holdings. Since that time, the ownership structure of the enterprise has not changed.

The main shareholder of the company is businessman Kirill Syrov, he owns 22.1% of offshore shares. Kirill Syrov is a secretive person, nothing is known about his business, in addition to Valent FARM. He is married to singer Anna Pletneva.

Kirill Syrov with his wife

In April 2021, Syrov fell ill with a severe coronavirus infection. He even ended up in the hospital. I wonder why the owner of Valenta Pharm did not take his essential drug Ingavirin. Perhaps he is also aware of its danger.

In October 2021, Syrov was involved in a serious motorcycle accident. With multiple open fractures and lacerations, he was taken to intensive care. He survived and recovered.

Footage from an accident with Syrov

But you need to go a little deeper. By far, Syrov owns the largest stake in the company, and accordingly receives the greatest benefit from the business. But the real decision in “Valenta PHARM” is another person. His share in the business is very small. And it does not belong to him personally, but to his mother Zinaida Reyhart – only 7%, but in fact, without this beneficiary – Dmitry Reyhart, Valenta FARM would not have achieved such success.

Reichart acquired his stake in Valenta Pharm in 2009. Prior to that, he held various positions in the system of the Ministry of Health of the Russian Federation. In 2006, he was appointed head of the Federal Compulsory Medical Insurance Fund. 4 months after Reichart was appointed to the department, there was a wave of arrests. In total, 11 FFOMS employees were arrested, who were accused of taking bribes totaling 27 million rubles. But Reyhart passed. Nobody touched him, and after 2 years he left his position of his own free will, and hit the business. Actually, the origin of Reyhart from official circles, and helps the manufacturer of Ingavirin “Valente Pharm” to be in the top sales of its own drug among the population, and enjoy significant success among government agencies.

Dmitry Reyhart

coronavirus scandal

As we have already mentioned in previous materials, experts doubted the therapeutic function of Ingavirin due to the fact that until 2014 another drug, Dicarbamine, was produced with the same active substance. In 2014, Valenta Pharm sent a letter to the Ministry of Health with a request to revoke the license of the drug. The reason for this step is unknown.

Based on this letter, on May 12, 2014, the Ministry of Health canceled the registration of the drug.

Letter of Cancellation of Dicarbamine Registration

In the future, a few years later, another drug with a similar formulation appears – Ingavirin, which in the next few years will be included in the list of vital and essential drugs. One substance against cancer and SARS. Not being a doctor, it’s obvious that things aren’t clean here.

Until 2020, no one remembered this situation until the coronavirus epidemic. At the end of 2020, Valenta Pharm began testing Ingavirin on volunteers as a cure for Covid. By Decree of the Government of the Russian Federation of 04/03/2021 No. 441, the manufacturer was allowed to complete the test ahead of schedule and release Ingavirin for free sale.

But Valenta Pharm, in principle, did not care about all these conventions. Back in January 2020, Ingavirin was advertised on all possible advertising platforms as a medicine against coronavirus, which, by the way, was not yet officially in Russia. But money is the most important thing. Employees of the Department for Control of Advertising and Unfair Competition of the Federal Antimonopoly Service of Russia then traced the advertisement for violations of the current legislation, and … that’s it! Nothing happened next. It is not clear how Ingavirin really became the main medicine against the coronavirus pandemic.

global purge

Anti-advertising is also advertising. In the case of Ingavirin and Valenta Pharm, this rule does not work. You can hardly get billions in bargains for a drug against a virus that can cause leukemia.

Therefore, “Valenta” does not disdain to clean up materials about the dangers of the drug. But the company is not going in the usual way – not through the courts. It is better for them to pay good fees to the authors of investigations about Ingavirin for removing materials about the dangers of the drug. Thus, publications about Ingavirin have already disappeared from several websites, VKontakte pages and YouTube channels.

If Valenta PHARM has nothing to hide, why can’t pharmacists answer journalists’ questions and try in every possible way to hide any information about their flagship drug. Obviously, the case is not clean, and they have something to hide.